President Joe Biden (White House Photo)

Biden Admin’s DOJ Loses Bid To Stop Major Healthcare Deal

In a blow to the Biden administration’s efforts to beef up antitrust enforcement, a federal judge on Monday rejected the Department of Justice’s (DOJ) efforts to halt UnitedHealth Group’s $13 billion acquisition of data and payment processing firm Change Healthcare.
by John Hugh DeMastri  Photo Source: White House

In a blow to the Biden administration’s efforts to beef up antitrust enforcement, a federal judge on Monday rejected the Department of Justice’s (DOJ) efforts to halt UnitedHealth Group’s $13 billion acquisition of data and payment processing firm Change Healthcare.

Stricter antitrust enforcement has been a goal of the Biden administration since an executive order last summer charged enforcement agencies to be more aggressive in a bid to “increase competition” and reduce the power of large conglomerates.

The DOJ argued that since UnitedHealth’s rivals in the insurance industry use Change Healthcare’s systems to compete with UnitedHealth, it was improper for UnitedHealth to be allowed to own Change, according to The Wall Street Journal.

In the news: Florida Gov. Ron DeSantis Lambasts Critics On Migrant Flights, Biden Policy

However, the Trump-appointed Judge Carl J. Nichols ruled in favor of the deal, under the condition that Change sell subsidiary ClaimsXten, as planned, in a one-page court order.

The deal, which would formally combine Change Healthcare with UnitedHealth’s service arm, Optum, has been touted by Optum as an opportunity for the two companies to combine their powers to offer simpler, more efficient services for patients, providers, and payers.

A UnitedHealth Group spokesperson told the Daily Caller News Foundation that the conglomerate was hoping the deal could be processed quickly, “so that together we can continue our work to make the health system work better for everyone.”

Despite successfully negotiating a nearly $85 million settlement from poultry producers this summer for antitrust violations, the administration has struggled in recent weeks to maintain its tough stance on antitrust.

A bill to break up Big Tech has stalled in Congress, and the Federal Trade Commission (FTC) recently lost a case to prevent biotechnology firm Illumina from purchasing cancer-testing firm Grail, according to The Wall Street Journal.

“We respectfully disagree with the court’s decision and are reviewing the opinion closely to evaluate next steps,” said Assistant Attorney General Johnathan Kanter, speaking on behalf of the DOJ’s Antitrust Division in a statement. “Protecting competition and access to affordable healthcare is of the utmost importance to the Antitrust Division and the Department of Justice.”

In the news: Siblings In Florida Charged With Attempted Murder In Horrific ‘Road Rage’ Crash

A ruling is expected on the DOJ’s suit attempting to thwart a deal between publishers Penguin Random House and Simon & Schuster, the WSJ reported. Should the deal go through, their combined market share would account for roughly a third of all book sales in the U.S., and combine the largest and third-largest publishers in the country, according to the WSJ.

Visit Tampafp.com for PoliticsSports, and National Headlines. Support journalism by clicking here to our GiveSendGo or sign up for our free newsletter by clicking here

Android Users, Click Here To Download The Free Press App And Never Miss A Story. Follow Us On Facebook Here Or Twitter Here.

Copyright 2022 The Free Press, LLC, tampafp.com. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Login To Facebook To Comment